Healthcare
Can GLP-1 drugs help people stop throwing away their money?
Researchers will explore whether weight-loss drugs can deter risky or impulsive financial decisions. "It might be very good financially for the average person,…
Keyword
GLP-1
1 stories in the last 7 days, reading bearish overall. Coverage in the last day was about normal.
- 7-day mood
- −28.0Bearish −28
- Stories, 7 days
- 1
- Last 24 hours
- 1no baseline yet
- Sources
- 13in the latest 30
Mood and coverage · last 7 days
Market chart- GLP-1 · 6-hour average
- Hourly reading
- Stories per hour
View as table
| Day | Mood | Stories |
|---|---|---|
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | −28.0 | 1 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
| Fri, Oct 2 | — | 0 |
Latest on GLP-1
Newest firstHealthcare
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes - much like a GLP-1.
Healthcare
Taking Ozempic? A routine eye exam could help you understand your risk for vision loss.
Some research suggests that GLP-1 drugs may raise the risk of a rare eye disease that causes full or partial vision loss.
Consumer
How GLP-1 weight-loss drugs are changing fast-food menus
Chipotle, McDonald's and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs.
Healthcare
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs?
The FDA has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts."
Consumer
Brian Sozzi's hot take: McDonald's GLP-1 stat is ridiculous
Brian Sozzi's hot take: McDonald's GLP-1 stat is ridiculous
Healthcare
This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound. Its stock is soaring.
Healthcare
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
Healthcare
Pritzker says he's lost 80 pounds on GLP-1 since diabetes diagnosis
The Illinois governor reveals he's been on a GLP-1 since being diagnosed with Type 2 diabetes two years ago.
Healthcare
Dem With Sights On 2028 Presidential Bid Loses 80 Pounds With Fat Shot
Illinois Democratic Governor JB Pritzker, who was labeled a "big fat slob" by President Donald Trump, revealed on Monday that he has lost 80 pounds thanks to a…
Healthcare
Why it may become harder to get coverage for GLP-1 weight-loss drugs
For those who rely on the medications, the difference between health plans that cover them and those that don't can mean hundreds of dollars a month.
Healthcare
Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says
The firm upgraded the pharmaceutical stock to buy from hold.
Healthcare
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Healthcare
GLP-1's benefits go beyond weight loss, Novonordisk CEO Mike Doustdar says.
GLP-1's benefits go beyond weight loss, Novonordisk CEO Mike Doustdar says.
Consumer
I'm a dietitian, and these are the 10 Costco groceries I'd stock up on if I were on a GLP-1
I'm a dietitian, and these are the 10 Costco groceries I'd stock up on if I were on a GLP-1
Healthcare
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Healthcare
A breast implant maker's stock could climb as GLP-1 market booms, TD Securities says
Establishment Labs is poised to get a boost from widening GLP-1 use as it is set to expand its breast implant business in the U.S., per TD Securities.
Healthcare
After a sell-off, this medical device stock looks like a gift for patient investors
Overblown fears surrounding GLP-1 weight loss drugs were already pressuring the stock when an onboarding stumble triggered a sell-off.
Healthcare
US nutrition startup Berry Street merges with India's Healthify as GLP-1 trends upwards
Berry Street founder Noah Kotlove and Healthify founder Tushar Vashisht will act as co-CEOs of the new entity.
Healthcare
New daily diabetes pill that helps with weight loss launches in UK pharmacies
Foundayo will be available on private prescription, with pharmacists warning of counterfeit GLP-1 problemA new daily pill that treats diabetes and helps with w…
Healthcare
Hims & Hers CEO says FTC lawsuit misunderstands how the company works
Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the company, compounded GLP-1 drugs and AI.
Healthcare
Obesity drugs show early promise against the hormonal disorder PMOS, giving a suffering family hope
A small but growing body of research shows that GLP-1 drugs often used to treat obesity may also work for the hormonal disorder known as PMOS
Healthcare
Can taking weight-loss drugs help you get hired? Yes, if you're a woman.
Going on GLP-1 drugs significantly boosted unemployed women's chances of finding a job, according to a Harvard economist.
Healthcare
GLP-1 drugs are fueling the rise of the 'big kids' market, one mega restaurant chain says
GLP-1 drugs are fueling the rise of the 'big kids' market, one mega restaurant chain says
Consumer
Starbucks is ending GLP-1 coverage for weight loss as employer costs climb
Starbucks is ending GLP-1 coverage for weight loss as employer costs climb
Healthcare
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Healthcare
Jim Cramer says he's standing by Eli Lilly after rival's GLP-1 lawsuit. Here's why
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
Healthcare
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The Danish company Novo says U.S.-based Lilly isn't including the most up-to-date clinical information about its drugs.
Healthcare
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.
Healthcare
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
